Sensei Bio

We look forward to presenting at PEGS Europe: Protein and Antibody Engineering Summit and Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. For additional details read the full press release here: https://lnkd.in/eNDR5DFg #PEGSEurope #SITC2024

This week, our Senior Director, Biologics Discovery & Early Development, Thomas Thisted PhD, presented an overview of our first conditionally active bispecific program, SNS-201, at the 15th Annual World Bispecific Summit. View the presentation here: https://lnkd.in/eb-383u6

We’re excited to present preclinical data on our conditionally active SNS-103 program targeting CD39 at the upcoming CRI-ENCI Eighth International Cancer Immunotherapy Conference. More info here: https://lnkd.in/e4vrVgME

This month, Sensei’s management will present at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference. For additional details read the full press release: https://lnkd.in/dRECbpNK

Earlier this month, our Boston and Rockville colleagues converged in the Poconos for our third annual science retreat, where we shared key learnings featuring scientific presentations from our team and celebrated our recent progress. We were also joined by keynote speaker, Dr. Andrea Cercek, gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, who sparked insightful discussions about the treatment landscape and high unmet needs of patients. During the retreat, our intellectual pursuits were balanced with some much-needed time in nature, enjoying team-building exercises, and moments of relaxation in the stunning Poconos landscape. A big thank you to everyone who made this a memorable and productive experience. Your enthusiasm, collaboration, and dedication are what drive our success. See you back at the office!

Today we reported our second quarter 2024 financial results and provided a corporate update.  To learn more about our recent advancements and upcoming milestones, read the full press release here: https://lnkd.in/eHGh9e3Y

Our SNS-101 poster is up. Please come by and say hi. We’re in Hall A, poster 79. #ASCO24

Don’t miss our investor webcast on Monday, June 3 at 8:00 am ET, featuring Shiraj Sen, Medical Oncologist and Director of Clinical Research at NEXT Oncology, Dallas, and a principal investigator for the SNS-101 study. The live event can be assessed here: https://lnkd.in/eGRRC9hu    We will discuss the clinical data from the Phase 1 dose escalation study of SNS-101, being presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1, 2024. #ASCO2024   SNS-101 is a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation). Tune in!     For additional detail, read the full press release here: https://lnkd.in/epX3Y2bY

Next week, Company’s management will present a corporate update at Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.     To register and tune in for this event, click here: https://lnkd.in/dSYYmrgB   For additional details read the full press release: https://lnkd.in/dKWyy5-y   #JefferiesHealthcare 

Next week, Sensei’s Chief Business Officer Stephanie Krebs will attend the annual Biotechnology Innovation Organization International Convention, being held in San Diego, CA from June 3-6, 2024. Please reach out if you would like an update on our lead program, SNS-101 and the exciting progress we’re making. See you there! #BIO2024